ABSTRACT
Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis. Relationships between self-evaluation parameters and personal features, psychopathological and psychophysiological parameters of patients, drug action characteristics, and course treatment effectiveness have been analyzed. Results suggest that the self-rated high tolerability of ladasten treatment is comparable with that of placebo. No relationships are found between the self-evaluated single-dose effects of ladasten and personal features of patients. Correlations of the self-estimations and some psychopathological and psychophysiological parameters before treatment, main drug effects, and overall course treatment effectiveness are revealed, whereas the self-evaluation of placebo effect was related to personal features.
Subject(s)
Adamantane/analogs & derivatives , Affect/drug effects , Anti-Anxiety Agents/therapeutic use , Motor Activity/drug effects , Neurasthenia/drug therapy , Adamantane/administration & dosage , Adamantane/therapeutic use , Administration, Oral , Adult , Anti-Anxiety Agents/administration & dosage , Diagnostic Self Evaluation , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Neurasthenia/diagnosis , Neurasthenia/physiopathology , Physical Examination , Placebo Effect , Psychophysiology , Research Design , Sleep Initiation and Maintenance Disorders , Sleep Stages , Treatment OutcomeABSTRACT
Self-evaluation of single-dose (15 mg) action and course treatment (30 mg daily) results were studied in patients with anxiety and asthenic disorders treated with the new anxiolytic afobazole. Also, relationships between self-evaluated parameters and personal features, clinician-rated therapeutic changes, and treatment effectiveness were analyzed. The study was conducted according to formalized protocol using standard scales and methods. Results suggest that higher self-rated tolerability and patient acceptability were associated with afobazole treatment in comparison to benzodiazepines. The results revealed relationships between self-evaluated single-dose effects of afobazole and other parameters, personal features, cognitive impairments severity, main drug effects, and overall treatment effectiveness.
Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Asthenia/drug therapy , Benzimidazoles/therapeutic use , Diagnostic Self Evaluation , Morpholines/therapeutic use , Adolescent , Adult , Anti-Anxiety Agents/administration & dosage , Anxiety/psychology , Asthenia/psychology , Benzimidazoles/administration & dosage , Cognition Disorders/etiology , Cognition Disorders/psychology , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Morpholines/administration & dosage , Neuropsychological Tests , Patient Compliance , Patient Satisfaction , Severity of Illness Index , Treatment Outcome , Young AdultABSTRACT
An aim of a randomized blind study was to assess therapeutic efficacy and safety of ladasten used as an antiastenic drug in patients with neurasthenia. Tasks of the study included the investigation of characteristics of therapeutical actions, efficacy of the drug comparing to placebo, possible side-effects and probability of the development of "withdrawal syndromes". The design of the study included a wash-out period, a monotherapy with ladasten and placebo during 28 days and a final 1-week period of receiving placebo. Standartisized objective and subjective methods of mental state evaluation in patients were administered. The results obtained suggest that a combination of psychostimulant and anxiolytic actions in the spectrum of psychotropic activity of ladasten determines the its high therapeutic efficacy in asthenic disorders. It has been found that ladasten is superior in the rate and degree of reduction of main symptoms of asthenic syndrome compared to placebo. The absence of "withdrawal syndrome" after the drug withdrawal reveals the lack of addictive potential in this drug.
Subject(s)
Adamantane/analogs & derivatives , Anti-Anxiety Agents/therapeutic use , Central Nervous System Stimulants/therapeutic use , Neurasthenia/drug therapy , Adamantane/administration & dosage , Adamantane/therapeutic use , Anti-Anxiety Agents/administration & dosage , Central Nervous System Stimulants/administration & dosage , Humans , Neurasthenia/diagnosis , Placebos , Time Factors , Treatment OutcomeABSTRACT
Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders. The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.
